MacroGenics Doses First Patient in Phase 1 Trial of Novel ADC MGC030

  • First patient dosed in Phase 1 trial of MGC030, an undisclosed-target ADC for advanced solid tumors.
  • Study will enroll up to 54 patients across multiple tumor types, including urothelial and pancreatic cancers.
  • MGC030 uses Synaffix’s proprietary ADC technology and SYNtecan E™ topoisomerase I inhibitor-based linker-payload.
  • Third ADC in MacroGenics’ active clinical development pipeline.

MacroGenics’ Phase 1 trial of MGC030 marks another step in the biotech’s push to expand its ADC pipeline, a key growth area in oncology. The study’s focus on advanced solid tumors aligns with broader industry trends toward precision therapies for hard-to-treat cancers. Success here could validate Synaffix’s ADC technology and strengthen MacroGenics’ position in the competitive ADC space.

Clinical Efficacy
Whether MGC030’s preclinical antitumor activity translates into meaningful clinical responses in advanced solid tumors.
Pipeline Momentum
How the advancement of MGC030 impacts MacroGenics’ broader ADC development strategy.
Target Disclosure
When MacroGenics will reveal the undisclosed antigen target for MGC030 and its competitive positioning.